Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2020-05-27 Diamyd Medical Diamyd Medical AB: Resultat från klinisk studie med Diamyd[®] i barn med hög risk för typ 1-diabetes Pressreleaser Ladda ner | Visa Stäng
2020-05-27 Diamyd Medical Diamyd Medical AB: Results from clinical trial with Diamyd[®] in children at high risk for type 1 diabetes Pressreleaser Ladda ner | Visa Stäng
2020-05-15 Diamyd Medical Diamyd Medical AB: Diamyd Medical kommer att teckna fullt ut sin andel i företrädesemission i NextCell Pharma Pressreleaser Ladda ner | Visa Stäng
2020-05-04 Diamyd Medical Diamyd Medical AB: Promising findings from the first part of a clinical trial with Remygen[®] Pressreleaser Ladda ner | Visa Stäng
2020-05-04 Diamyd Medical Diamyd Medical AB: Lovande fynd från första delen av klinisk studie med Remygen[®] Pressreleaser Ladda ner | Visa Stäng
2020-04-24 Diamyd Medical Diamyd Medical AB: Japan beviljar patent för intralymfatisk administration av diabetesvaccinet Diamyd® Pressreleaser Ladda ner | Visa Stäng
2020-04-24 Diamyd Medical Diamyd Medical AB: Japan grants patent for intralymphatic administration of the diabetes vaccine Diamyd® Pressreleaser Ladda ner | Visa Stäng
2020-04-16 Diamyd Medical Diamyd Medical AB: Diamyd Medical opens up for vaccine manufacturing in Umeå, Sweden Pressreleaser Ladda ner | Visa Stäng
2020-04-16 Diamyd Medical Diamyd Medical AB: Diamyd Medical öppnar upp för vaccintillverkning i Umeå Pressreleaser Ladda ner | Visa Stäng
2020-04-14 Diamyd Medical Diamyd Medical AB: The European Patent Office grants patent for intralymphatic administration of the diabetes vaccine Diamyd® Pressreleaser Ladda ner | Visa Stäng
2020-04-14 Diamyd Medical Diamyd Medical AB: Europeiska patentverket beviljar patent för intralymfatisk administration av diabetesvaccinet Diamyd® Pressreleaser Ladda ner | Visa Stäng
2020-03-26 Diamyd Medical Diamyd Medical AB: Penser Access: Diamyd - En positiv överraskning Pressreleaser Visa Stäng
2020-03-25 Diamyd Medical Diamyd Medical AB: Delårsrapport II 19/20 Rapporter Ladda ner | Visa Stäng
2020-03-25 Diamyd Medical Diamyd Medical AB: Quarterly Report II 19/20 Rapporter Ladda ner | Visa Stäng
Rapporter | 25 Mar 2020 | Diamyd Medical

Diamyd Medical AB: Quarterly Report II 19/20

Developing therapies for type 1 diabetes
Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.
Further information is available on https://www.diamyd.com

 

Figures in parentheses relate to the corresponding period previous financial year.

 

September 1, 2019 – February 29, 2020

  • Net result: MSEK 30.3 (-19.0), whereof second quarter MSEK 37.1 (-10.4). The increase is a one-off effect due to a payment of corresponding MSEK 48.0 from the previous GAD65 manufacturer as support for transition of the manufacturing process.
  • Result per share: SEK 0.4 (-0.3), second quarter SEK 0.5 (-0.2)
  • Cash flow from operating activities: MSEK 31.1 (-19.5), second quarter: MSEK 37.2 (-8.7)
  • Cash and cash equivalents at February 29, 2020: MSEK 88.3 (79.6)

 

Significant events second quarter, December 2019 – February 2020

  •  
  • DIAGNODE-1: Positive Top-line results from Phase I/II trial with intralymphatic Diamyd[®]
  • ReGenerate-1: The main part of the Phase I/II trial with Remygen[®] in type 1 diabetes started
  • Significant effect of Diamyd[® ]in Type 1 diabetes shown in comprehensive analysis of previous phase III and phase II trials

Significant events after the reporting period

  • GADinLADA: New trial with Diamyd[®] in autoimmune diabetes started recruiting patients in Norway
  •  

Comments by CEO Ulf Hannelius
The last weeks we have seen the Corona virus disease (COVID-19) outbreak creating turmoil in the financial markets and affecting the global economy. Given the prevailing times, we are fortunate at Diamyd Medical to have solid finances and a strong position with the diabetes vaccine Diamyd[®], our lead candidate.

 

First, SEK 88 million in cash and a current monthly burn rate of approximately SEK 3 million give us, with ongoing activities, a runway of at least two years. We will do our best to prioritize our resources wisely and to strengthen the foundation of the company, maximizing the value of our assets.

 

Second, our DIAGNODE-2 Phase IIb trial with Diamyd[®], was fully recruited already by May 2019, and all patients received their three injections long before the viral outbreak. We are now working closely with our partners to make sure to smooth operations as we are moving closer to finalizing the trial later this year.

 

Third, it is important to know that the antigen-specific immunotherapy Diamyd[®] does not weaken the immune system, opposed to immunosuppressive treatments that may increase the risk of infections by viral or other pathogens and/or predispose the patient to complications due to these infections. The safety profiles of both Diamyd[®] and our second clinical asset Remygen[®] are clear strengths, and in these times and going forward this may prove to become one of the most crucial advantages for Diamyd Medical.

 

Fourth, with the comprehensive responder analysis announced in December last year, we have improved the probability of success for Diamyd[®]. The results, which identified the genetics for the best Diamyd[®] responders, were in agreement with the thoughts on precision medicine that were independently proposed in a recent scientific review (Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes, Diabetes Care, January, 2020).

 

Last but not least, the DIAGNODE-2 results will be important in forming the final design of the pivotal Phase III program, and with the results from the responder analysis now at hand we have the confidence to move ahead in our preparations for building the commercial case for Diamyd[®].

 

Stockholm, March 25, 2020

Ulf Hannelius, President and CEO

 

 

Two drugs in clinical development

[][]
Diamyd[®] and Remygen[®] are drugs in clinical development that focus on the
underlying disease mechanisms of diabetes; the dysfunction and loss of insulin
-producing beta cells in the pancreas.

                         

Diamyd[®] is an antigen-specific immunotherapy for the treatment of autoimmune diabetes (type 1 diabetes).

Clinical data indicate the potential of the diabetes vaccine Diamyd[®] to halt or stop the autoimmune destruction of insulin-producing beta cells. The effect is achieved by antigen-specific reprogramming of immune cells by administration of low doses of Diamyd[®] in superficial lymph nodes.

By maintaining the endogenous insulin production, Diamyd[®] has the potential to make a significant difference in the daily life of patients as well significantly reduce the complications of type 1 diabetes.

Intralymphatic treatment with Diamyd[®] is now being investigated in a clinical Phase IIb trial (DIAGNODE-2), with the aim of confirming the previously demonstrated clinical effect from a pilot trial in type 1 diabetes patients (DIAGNODE-1).

 

Remygen[®] is an oral regenerative and immunomodulatory therapy for the treatment of autoimmune- and type 2 diabetes.

By stimulating the growth of insulin-producing cells, Remygen[®] has the potential to reverse the disease progression in autoimmune- and type 2 diabetes.

Remygen[®] is now being investigated in a clinical Phase I/II trial (ReGenerate-1), where clinical efficacy is evaluated with the aim of optimizing treatment ahead of registration-based trials.

 

Significant events during the second quarter

December 1, 2019 – February 29, 2020

 

Diamyd Medical entered agreement to facilitate transition of manufacturing

Diamyd Medical and Protein Sciences Corporation (PSC) entered into an agreement modifying their relationship, by which PSC will continue to support Diamyd Medical in its development of a diabetes vaccine but will no longer serve as its contract manufacturer. The agreement facilitates the transition of the manufacturing process of recombinant GAD65, the active ingredient in the diabetes vaccine Diamyd[®], to a new manufacturer for future anticipated commercial manufacture. PSC will support Diamyd Medical with in cash, as well as certain raw materials and up to 150 man-hours of technical assistance for the transition process. The agreement has been made in light of the announcement by Diamyd Medical in October 2019 where PSC had informed Diamyd Medical that it was unable to meet Diamyd Medical’s manufacturing needs for commercial supply. The payment was made in February 2020.

 

Positive Top-line results from Phase I/II trial with intralymphatic Diamyd[® ]

When all 12 patients had been followed throughout the 30-month period in the open-label trial DIAGNODE-1, the patients showed on average a positive clinical course with a near normal long-term blood sugar and a low need for externally supplied insulin. The three patients who received an extra Diamyd[®] injection into the lymph node after their 30-month visit showed a maintained own insulin production between the 30- and 43-month visits, as well as lower long-term blood sugar and insulin requirements compared to baseline. Safety looked good and no serious side effects had been reported.

 

The main part of the Phase I/II trial ReGenerate-1 with Remygen[®  ] started

Four patients had been included in the trial and additional patients were scheduled to be included in December and January. Compilation of metabolic results from the completed safety and dose escalation part of the trial awaits a final experimental analysis and is expected to be announced during the second quarter of 2020.

 

Significant effect of Diamyd[® ]in Type 1 diabetes shown in a comprehensive analysis of previous Phase III and Phase II trials

A new analysis based on data from more than 530 individual patients from previous Phase III and II trials in Europe and US with the diabetes vaccine Diamyd[®] identified genetically defined subgroups of type 1 diabetes patients that showed a positive and statistically significant dose-dependent treatment response.

 

 

Significant events after the reporting period

 

New trial with Diamyd[®] in autoimmune diabetes started recruiting patients in Norway

GADinLADA, the first clinical phase II trial with the diabetes vaccine Diamyd[®] administered directly into the lymph node in patients with LADA started recruitment at the Norwegian University of Science and Technology in Trondheim (NTNU), in cooperation with St. Olav’s University Hospital, Trondheim. The trial will also be conducted in Sweden at the Center for Diabetes, the Academic Specialist Center, an academic specialist unit that is run in collaboration between the Health Care Services Stockholm County, Karolinska Institute and Karolinska University Hospital, and the recruitment is expected to start during the spring. In total, the trial encompasses 15 patients between the ages of 30 to 70 years diagnosed with LADA within the last 12 months who are not yet on insulin therapy.

 

 

Ongoing clinical trials

Type 1 diabetes is a devastating disease which requires daily treatment with insulin to sustain life. The importance of finding a drug that improves the prospects for patients with diabetes is of utmost importance. The effect of intralymphatic administration of Diamyd[®], an antigen-specific immunotherapy aimed at stopping the immune system’s attack on insulin-producing beta cells in autoimmune diabetes, is evaluated in the Phase IIb trial DIAGNODE-2. Remygen[®], which aims to stimulate the growth of beta cells in patients with diabetes, is now evaluated in patients in a Phase I/II trial.

 

Trials with Diamyd® in lymph node

  • DIAGNODE -2 – DIAMYD[®] IN LYMPH NODES WITH ORAL SUPPLEMENTATION OF VITAMIN D

A follow-up double-blind randomized clinical trial where Diamyd[®] is administered directly into a lymph node with oral supplements of vitamin D. The trial encompasses 109 patients from Sweden, the Czech Republic, Spain and the Netherlands, aged 12-24 years who have recently been diagnosed with type 1 diabetes and will continue for a total of 15 months. As of autumn 2019, those patients who have not performed their last visit at 15 months are invited to participate in a nine months extension of the trial. 15-month results are expected to be presented in the third quarter of 2020. The aim of the trial is to evaluate the patients’ remaining insulin producing capacity. Coordinating Investigator is Professor Johnny Ludvigsson at Linköping University, Sweden. Diamyd Medical is the Sponsor of the trial.

 

  • GADinLADA – DIAMYD[®] IN LYMPH NODES WITH ORAL SUPPLEMENTATION OF VITAMIN D

An open-label, investigator initiated clinical trial where Diamyd[®] is administered directly into a lymph node with oral supplements of vitamin D. The trial encompasses 15 patients aged 30-70 years diagnosed with LADA (Latent Autoimmune Diabetes in Adults) and not yet on inulin treatment. The aim with the trial is to evaluate the safety of intralymphatic treatment with Diamyd[® ]in LADA patients and to continuously evaluate the immunological and clinical response during a one-year period. Sponsor of the trial is the Norwegian University of Science and Technology with Ingrid K Hals as sponsor representative.

 

 

Trial with Remygen® (GABA)

  • REGENERATE-1 – REMYGEN[®] /ALPRAZOLAM

An open-label, investigator initiated clinical trial with Remygen[®]. The trial includes approximately 36 patients aged 18-50 who have had type 1 diabetes for more than five years with low to non-existing insulin production. The primary aim of the trial is to in a smaller dose escalation section evaluate the safety of Remygen[®]. The main trial also evaluates whether the insulin-producing cells can be regenerated using Remygen[®], and in the combination of Remygen[®] and Alprazolam. The trial is led by Professor Per-Ola Carlsson at Uppsala University, Sponsor of the trial.

 

Other ongoing trial with Diamyd®

  • DiAPREV-IT 2 – COMBINING DIAMYD[®] WITH VITAMIN D

A placebo-controlled investigator-initiated clinical trial, where Diamyd[®] is given subcutaneously and being tested in combination with vitamin D in children at high risk of developing type 1 diabetes, meaning that they have been found to have an ongoing autoimmune process but do not yet have any clinical symptoms of diabetes. The trial includes 26 children and results are expected in Q2 2020. The aim of the trial is to evaluate whether Diamyd[®] can delay or prevent the participants from presenting with type 1 diabetes. The trial is led by Dr. Helena Elding Larsson at Lund University, Sweden, Sponsor of the trial.

 

2020-03-02 Diamyd Medical Diamyd Medical AB: New trial with Diamyd[®] in autoimmune diabetes has started recruting patients in Norway Pressreleaser Ladda ner | Visa Stäng
2020-03-02 Diamyd Medical Diamyd Medical AB: Ny studie med Diamyd[®] i autoimmun diabetes har startat rekryteringen av patienter i Norge Pressreleaser Ladda ner | Visa Stäng
2020-02-05 Diamyd Medical Diamyd Medical AB: Diamyd Medical enters agreement to facilitate transition of manufacturing Pressreleaser Ladda ner | Visa Stäng
2020-02-05 Diamyd Medical Diamyd Medical AB: Diamyd Medical når överenskommelse för flytt av tillverkning Pressreleaser Ladda ner | Visa Stäng
2020-02-03 Diamyd Medical Diamyd Medical AB: Diamyd Medical presenterar denna vecka på LSX World Congress och Swiss-Nordic Bio 2020 Pressreleaser Ladda ner | Visa Stäng
2020-02-03 Diamyd Medical Diamyd Medical AB: Diamyd Medical to present this week at LSX World Congress and at Swiss-Nordic Bio 2020 Pressreleaser Ladda ner | Visa Stäng
2020-01-23 Diamyd Medical Diamyd Medical AB: Penser Access: Diamyd Medical - Ny analys ger stöd för uppvärdering Pressreleaser Visa Stäng
2020-01-22 Diamyd Medical Diamyd Medical AB: Delårsrapport I 19/20 Rapporter Ladda ner | Visa Stäng
2020-01-22 Diamyd Medical Diamyd Medical AB: Quarterly Report I 19/20 Rapporter Ladda ner | Visa Stäng
2019-12-20 Diamyd Medical Diamyd Medical AB: Positiva top-line-resultat från fas I/II-studie med Diamyd[®] i lymfkörtel Pressreleaser Ladda ner | Visa Stäng
2019-12-20 Diamyd Medical Diamyd Medical AB: Positive Top-line results from I/II trial with intralymphatic Diamyd[®] [] Pressreleaser Ladda ner | Visa Stäng
2019-12-17 Diamyd Medical Diamyd Medical AB: Update from the Phase I/II trial ReGenerate-1 with Remygen[®] [] Pressreleaser Ladda ner | Visa Stäng
2019-12-17 Diamyd Medical Diamyd Medical AB: Uppdatering från fas I/II-studien ReGenerate-1 med Remygen[®] Pressreleaser Ladda ner | Visa Stäng
2019-12-17 Diamyd Medical Diamyd Medical AB: Annual Report 18/19 Rapporter Ladda ner | Visa Stäng
2019-12-12 Diamyd Medical Diamyd Medical AB: Significant effect of Diamyd[®] in Type 1 diabetes shown in a new comprehensive analysis of previous Phase III and Phase II trials Pressreleaser Ladda ner | Visa Stäng
2019-12-12 Diamyd Medical Diamyd Medical AB: Signifikant effekt av Diamyd[®] i typ 1-diabetes visad i ny omfattande analys av tidigare fas III- och fas II-studier Pressreleaser Ladda ner | Visa Stäng
2019-11-21 Diamyd Medical Bulletin from Annual General Meeting of Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2019-11-21 Diamyd Medical Kommuniké från årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2019-11-11 Diamyd Medical Diamyd Medical AB: Positiv säkerhetsanalys av Remygen[®] ger klartecken för start av nästa del av fas I/II-studie i typ 1-diabetespatienter Pressreleaser Ladda ner | Visa Stäng
2019-11-11 Diamyd Medical Diamyd Medical AB: Positive safety review of Remygen[®] gives clearance to start next part of Phase I/II trial in type 1 diabetes patients Pressreleaser Ladda ner | Visa Stäng
2019-10-31 Diamyd Medical Diamyd Medical AB: Årsredovisning 18/19 Rapporter Ladda ner | Visa Stäng
2019-10-24 Diamyd Medical Kallelse till årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2019-10-17 Diamyd Medical Diamyd Medical AB: Diamyd Medicals tillverkningsprocess kan komma att flyttas till ny tillverkare Pressreleaser Ladda ner | Visa Stäng
2019-10-17 Diamyd Medical Diamyd Medical AB: Diamyd Medical's manufacturing process may be moved to a new manufacturer Pressreleaser Ladda ner | Visa Stäng
2019-10-15 Diamyd Medical Diamyd Medical AB: Diamyd Medical ingår avtal om intralymfatisk Diamyd ® -studie i LADA Pressreleaser Ladda ner | Visa Stäng
2019-10-15 Diamyd Medical Diamyd Medical AB: Diamyd Medical enters agreement for intralymphatic Diamyd ® trial in LADA Pressreleaser Ladda ner | Visa Stäng
2019-10-03 Diamyd Medical Diamyd Medical AB: Penser Access: Diamyd Medical - Stor potential trots negativ studie Pressreleaser Visa Stäng
2019-10-02 Diamyd Medical Diamyd Medical AB: Year-End Report 18/19 Rapporter Ladda ner | Visa Stäng
2019-10-02 Diamyd Medical Diamyd Medical AB: Bokslutskommuniké 18/19 Rapporter Ladda ner | Visa Stäng
2019-09-17 Diamyd Medical Diamyd Medical AB: Preliminära resultat från GABA/Diamyd®-studie Pressreleaser Ladda ner | Visa Stäng
2019-09-17 Diamyd Medical Diamyd Medical AB: Preliminary results from GABA/Diamyd® trial Pressreleaser Ladda ner | Visa Stäng
2019-09-16 Diamyd Medical Diamyd Medical AB: Patienter kommer att erbjudas längre deltagande i den europeiska fas IIb-studien med diabetesvaccinet Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-09-16 Diamyd Medical Diamyd Medical AB: Patients will be offered longer participation in the European Phase IIb trial with the diabetes vaccine Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-09-09 Diamyd Medical Diamyd Medical AB: Genomförbarhetsstudie stöder användningen av intralymfatiska injektioner av Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-09-09 Diamyd Medical Diamyd Medical AB: Feasibility study supports the use of intralymphatic injections of Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-08-27 Diamyd Medical Diamyd Medical AB: Timeline update on GABA/Diamyd® and Remygen® clinical trials Pressreleaser Ladda ner | Visa Stäng
2019-08-27 Diamyd Medical Diamyd Medical AB: Uppdatering om tidplanerna för kliniska studier med GABA/Diamyd® och Remygen® Pressreleaser Ladda ner | Visa Stäng
2019-06-27 Diamyd Medical Diamyd Medical AB: Penser Access: Diamyd Medical - Resultat från fas IIb-studien under Q3'20 Pressreleaser Visa Stäng
2019-06-26 Diamyd Medical Diamyd Medical AB: Quarterly Report III 18/19 Rapporter Ladda ner | Visa Stäng
2019-06-26 Diamyd Medical Diamyd Medical AB: Delårsrapport III 18/19 Rapporter Ladda ner | Visa Stäng
2019-06-18 Diamyd Medical Diamyd Medical AB: Diamyd Medicals intralymfatiska diabetesterapi väcker ökat intresse Pressreleaser Ladda ner | Visa Stäng
2019-06-18 Diamyd Medical Diamyd Medical AB: Diamyd Medical's intralymphatic diabetes therapy attracts increased interest Pressreleaser Ladda ner | Visa Stäng
2019-06-10 Diamyd Medical Diamyd Medical AB: Diamyd Medical fully subscribes to its pro rata share in NextCell Pharma's rights issue Pressreleaser Ladda ner | Visa Stäng
2019-06-10 Diamyd Medical Diamyd Medical AB: Diamyd Medical tecknar full ut sin andel i NextCell Pharmas företrädesemission Pressreleaser Ladda ner | Visa Stäng
2019-06-04 Diamyd Medical Diamyd Medical AB: Ny delrapport vid 30 månader och efter extra injektion stödjer långtidseffekt av intralymfatisk Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-06-04 Diamyd Medical Diamyd Medical AB: New interim report at 30 months and after extra injection supports long-term effect of intralymphatic Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-05-29 Diamyd Medical Diamyd Medical AB: The Swedish Medical Products Agency approves new treatment arm with Remygen® and Alprazolam in Phase I/II trial ReGenerate-1 Pressreleaser Ladda ner | Visa Stäng
2019-05-29 Diamyd Medical Diamyd Medical AB: Läkemedelsverket godkänner ny behandlingsarm med Remygen® och Alprazolam i fas I/II-studien ReGenerate-1 Pressreleaser Ladda ner | Visa Stäng
2019-05-13 Diamyd Medical Diamyd Medical AB: Huvudägare minskar innehav i Diamyd Medical med 0,6% Pressreleaser Ladda ner | Visa Stäng
2019-05-07 Diamyd Medical Diamyd Medical AB: Fully recruited European Phase IIb trial with the diabetes vaccine Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-05-07 Diamyd Medical Diamyd Medical AB: Fullrekryterad europeisk fas IIb-studie med diabetesvaccinet Diamyd® Pressreleaser Ladda ner | Visa Stäng
2019-04-16 Diamyd Medical Diamyd Medical AB: Resultat från EDCR IIa-studien där Diamyd® ges subkutant Pressreleaser Ladda ner | Visa Stäng
2019-04-16 Diamyd Medical Diamyd Medical AB: Results from the EDCR IIa trial where Diamyd® is given subcutaneously Pressreleaser Ladda ner | Visa Stäng
2019-04-11 Diamyd Medical Diamyd Medical AB: Immunological findings supporting intralymphatic treatment with Diamyd® to be presented today at a diabetes meeting in Stockholm Pressreleaser Ladda ner | Visa Stäng
2019-04-11 Diamyd Medical Diamyd Medical AB: Immunologiska resultat som stödjer intralymfatisk behandling med Diamyd® presenteras idag vid diabeteskonferens i Stockholm Pressreleaser Ladda ner | Visa Stäng
2019-03-28 Diamyd Medical Diamyd Medical AB: Penser Access: Diamyd Medical - DIAGNODE-2 nära fullrekryterad Pressreleaser Visa Stäng
2019-03-27 Diamyd Medical Diamyd Medical AB: Delårsrapport II 18/19 Rapporter Ladda ner | Visa Stäng
2019-03-27 Diamyd Medical Diamyd Medical AB: Quarterly Report II 18/19 Rapporter Ladda ner | Visa Stäng
2019-03-26 Diamyd Medical Diamyd Medical AB: Diamyd Medical informerar om strategiska aktiviteter 2019 och 2020 Pressreleaser Ladda ner | Visa Stäng
2019-03-26 Diamyd Medical Diamyd Medical AB: Diamyd Medical announces strategic activities for 2019 and 2020 Pressreleaser Ladda ner | Visa Stäng
2019-03-08 Diamyd Medical Diamyd Medical AB: Europeisk fas IIb-studie i typ 1-diabetes med diabetesvaccinet Diamyd® nära fullrekrytering Pressreleaser Ladda ner | Visa Stäng
2019-03-08 Diamyd Medical Diamyd Medical AB: European Phase IIb trial in type 1 diabetes with the diabetes vaccine Diamyd® close to being fully recruited Pressreleaser Ladda ner | Visa Stäng
2019-03-04 Diamyd Medical Diamyd Medical AB: A new publication supports Diamyd Medical's patent rights around GABA Pressreleaser Ladda ner | Visa Stäng
2019-03-04 Diamyd Medical Diamyd Medical AB: Ny publikation stödjer Diamyd Medicals patenträttigheter kring GABA Pressreleaser Ladda ner | Visa Stäng
2019-01-24 Diamyd Medical Penser Access: Diamyd - Finansiering säkrad Pressreleaser Visa Stäng
2019-01-23 Diamyd Medical Delårsrapport I 18/19 Rapporter Ladda ner | Visa Stäng
2019-01-23 Diamyd Medical Quarterly Report I 18/19 Rapporter Ladda ner | Visa Stäng
2018-11-28 Diamyd Medical Komplettering - Elva av tolv typ 1-diabetespatienter behandlade med intralymfatiskt Diamyd® i partiell remission vid 15 månader Pressreleaser Ladda ner | Visa Stäng
2018-11-26 Diamyd Medical Elva av tolv typ 1-diabetespatienter behandlade med intralymfatiskt Diamyd® i partiell remission vid 15 månader Pressreleaser Ladda ner | Visa Stäng
2018-11-26 Diamyd Medical Eleven out of twelve Type 1 diabetes patients treated with intralymphatic Diamyd® are in Partial Remission at 15 months Pressreleaser Ladda ner | Visa Stäng
2018-11-26 Diamyd Medical Diamyd Medical påminner om nyttjande av teckningsoptioner Pressreleaser Ladda ner | Visa Stäng
2018-11-15 Diamyd Medical Kommuniké från årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2018-11-15 Diamyd Medical Bulletin from Annual General Meeting of Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2018-11-15 Diamyd Medical Diamyd Medical updates on the Company and the diabetes vaccine Diamyd® ahead of the Annual General Meeting today Pressreleaser Ladda ner | Visa Stäng
2018-11-15 Diamyd Medical Diamyd Medical uppdaterar om Bolaget och diabetesvaccinet Diamyd® inför dagens årsstämma Pressreleaser Ladda ner | Visa Stäng
2018-11-14 Diamyd Medical Diamyd Medicals huvudägare ökar sin investering i Bolaget genom att fullt ut nyttja sina teckningsoptioner Pressreleaser Ladda ner | Visa Stäng
2018-11-01 Diamyd Medical Internationally renowned diabetes expert proposed to join Diamyd Medical's Board of Directors Pressreleaser Ladda ner | Visa Stäng
2018-11-01 Diamyd Medical Internationellt känd diabetesexpert föreslås till Diamyd Medicals styrelse Pressreleaser Ladda ner | Visa Stäng
2018-11-01 Diamyd Medical Nyttjandeperioden av teckningsoptioner i Diamyd Medical inleds idag Pressreleaser Ladda ner | Visa Stäng
2018-10-25 Diamyd Medical Årsredovisning 17/18 Rapporter Ladda ner | Visa Stäng
2018-10-23 Diamyd Medical New immunological results that support intralymphatic treatment with Diamyd® to be presented at the Immunology of Diabetes Society Congress Pressreleaser Ladda ner | Visa Stäng
2018-10-23 Diamyd Medical Nya immunologiska resultat som stödjer intralymfatisk behandling med Diamyd® presenteras på internationell diabeteskonferens Pressreleaser Ladda ner | Visa Stäng
2018-10-18 Diamyd Medical Kallelse till årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2018-10-16 Diamyd Medical The Phase I/II trial with Remygen® for the regeneration of insulin-producing cells is recruiting patients Pressreleaser Ladda ner | Visa Stäng
2018-10-16 Diamyd Medical Fas I/II-studien med Remygen® för återbildning av insulinproducerande celler rekryterar patienter Pressreleaser Ladda ner | Visa Stäng
2018-10-08 Diamyd Medical EP-Access: Diamyd Medical - På väg att lösa diabetesgåtan Pressreleaser Visa Stäng
2018-10-03 Diamyd Medical Year-End Report 17/18 Rapporter Ladda ner | Visa Stäng
2018-10-03 Diamyd Medical Bokslutskommuniké 17/18 Rapporter Ladda ner | Visa Stäng
2018-09-18 Diamyd Medical Diamyd Medical tydliggör målet att ansöka om tidigare marknadsgodkännande för Diamyd® Pressreleaser Ladda ner | Visa Stäng
2018-09-18 Diamyd Medical Diamyd Medical clarifies the goal of applying for earlier market approval for Diamyd® Pressreleaser Ladda ner | Visa Stäng
2018-09-11 Diamyd Medical Positive 15-month results with Diamyd® in Type 1 diabetes Pressreleaser Ladda ner | Visa Stäng
2018-09-11 Diamyd Medical Positiva 15-månadersresultat med Diamyd® i typ 1-diabetes Pressreleaser Ladda ner | Visa Stäng
2018-08-23 Diamyd Medical Diamyd Medical utnyttjar samtliga sina teckningsoptioner i NextCell Pharma Pressreleaser Ladda ner | Visa Stäng
2018-08-23 Diamyd Medical Diamyd Medical exercises all of its warrants in NextCell Pharma Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Diamyd Medical Strategisk utökning av Diamyd Medicals europeiska fas II-studie i typ 1-diabetes Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Diamyd Medical Strategic expansion of Diamyd Medical's European Phase II trial in Type 1 diabetes Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Diamyd Medical Strategic expansion of Diamyd Medical's European Phase II trial in Type 1 diabetes Pressreleaser Ladda ner | Visa Stäng
2018-08-21 Diamyd Medical Strategisk utökning av Diamyd Medicals europeiska fas II-studie i typ 1-diabetes Pressreleaser Ladda ner | Visa Stäng
2018-07-04 Diamyd Medical The GABA/Diamyd® trial in the US now fully recruited Pressreleaser Ladda ner | Visa Stäng
2018-07-04 Diamyd Medical Den amerikanska GABA/Diamyd®-studien nu fullrekryterad Pressreleaser Ladda ner | Visa Stäng
2018-06-27 Diamyd Medical Delårsrapport III 17/18 Rapporter Ladda ner | Visa Stäng
2018-06-27 Diamyd Medical Quarterly Report III 17/18 Rapporter Ladda ner | Visa Stäng
2018-06-13 Diamyd Medical Diamyd Medicals Remygen™ för återbildning av insulinproducerande celler godkänt för kliniska studier Pressreleaser Ladda ner | Visa Stäng
2018-06-13 Diamyd Medical Diamyd Medical's Remygen™ for regeneration of insulin-producing cells approved for clinical trials Pressreleaser Ladda ner | Visa Stäng
2018-05-18 Diamyd Medical Update regarding the manufacturing of Diamyd® drug substance Pressreleaser Ladda ner | Visa Stäng
2018-05-18 Diamyd Medical Uppdatering gällande tillverkning av Diamyd® läkemedelssubstans Pressreleaser Ladda ner | Visa Stäng
2018-05-16 Diamyd Medical Läkemedelsverket godkänner en extra injektion Diamyd® i pågående pilotstudie Pressreleaser Ladda ner | Visa Stäng
2018-05-16 Diamyd Medical Swedish MPA approves an additional injection of Diamyd® in ongoing clinical pilot trial Pressreleaser Ladda ner | Visa Stäng
2018-05-07 Diamyd Medical Resultat som stödjer intralymfatisk behandling med Diamyd® publicerade i Journal of Diabetes Research Pressreleaser Ladda ner | Visa Stäng
2018-05-07 Diamyd Medical Results supporting intralymphatic administration of Diamyd® published in the Journal of Diabetes Research Pressreleaser Ladda ner | Visa Stäng
2018-04-23 Diamyd Medical 50% enrollment milestone reached in Diamyd Medical's European Phase II trial Pressreleaser Ladda ner | Visa Stäng
2018-04-23 Diamyd Medical 50% rekryteringsmilstolpe uppnådd i Diamyd Medicals europeiska fas II-studie Pressreleaser Ladda ner | Visa Stäng
2018-04-05 Diamyd Medical Resultat om GABAs betydelse i diabetes, patentsökta av Diamyd Medical och forskare vid Uppsala universitet, har publicerats i eBioMedicine Pressreleaser Ladda ner | Visa Stäng
2018-04-05 Diamyd Medical Results showing GABA's relevance for diabetes, patent filed by Diamyd Medical and Uppsala University scientist, published in eBioMedicine Pressreleaser Ladda ner | Visa Stäng
2018-03-28 Diamyd Medical Delårsrapport II 17/18 Rapporter Ladda ner | Visa Stäng
2018-03-28 Diamyd Medical Quarterly Report II 17/18 Rapporter Ladda ner | Visa Stäng
2018-03-27 Diamyd Medical Diamyd® subcutaneously continues to show weaker results than when administered intralymphatically Pressreleaser Ladda ner | Visa Stäng
2018-03-27 Diamyd Medical Diamyd® subkutant fortsätter visa svagare resultat än om det ges intralymfatiskt Pressreleaser Ladda ner | Visa Stäng
2018-03-12 Diamyd Medical Delrapport från DIAGNODE-1 visar fortsatt positivt kliniskt förlopp Pressreleaser Ladda ner | Visa Stäng
2018-03-12 Diamyd Medical Interim report from DIAGNODE-1 shows continued positive clinical course Pressreleaser Ladda ner | Visa Stäng
2018-03-02 Diamyd Medical Operational update on the diabetes vaccine Diamyd® and recombinant GAD Pressreleaser Ladda ner | Visa Stäng
2018-03-02 Diamyd Medical Operationell uppdatering om diabetesvaccinet Diamyd® och rekombinant GAD Pressreleaser Ladda ner | Visa Stäng
2018-02-22 Diamyd Medical GABA/Diamyd®-studien fullrekryterad till sommaren Pressreleaser Ladda ner | Visa Stäng
2018-02-22 Diamyd Medical The GABA/Diamyd®   trial in the US fully recruited this summer Pressreleaser Ladda ner | Visa Stäng
2018-02-09 Diamyd Medical Stort intresse från patienter att delta i DIAGNODE-2-studien Pressreleaser Ladda ner | Visa Stäng
2018-02-09 Diamyd Medical High interest from patients to participate in the DIAGNODE-2 trial Pressreleaser Ladda ner | Visa Stäng
2018-01-24 Diamyd Medical Delårsrapport I 17/18 Rapporter Ladda ner | Visa Stäng
2018-01-24 Diamyd Medical Quarterly Report I 17/18 Rapporter Ladda ner | Visa Stäng
2018-01-08 Diamyd Medical The diabetes vaccine Diamyd® shows continued positive clinical course after 30 months Pressreleaser Ladda ner | Visa Stäng
2018-01-08 Diamyd Medical Diabetesvaccinet Diamyd® visar fortsatt positivt kliniskt förlopp efter 30 månader Pressreleaser Ladda ner | Visa Stäng
2017-12-11 Diamyd Medical Diabetesvaccinet Diamyd® visar positiva resultat Pressreleaser Ladda ner | Visa Stäng
2017-12-11 Diamyd Medical The diabetes vaccine Diamyd® shows positive results Pressreleaser Ladda ner | Visa Stäng
2017-11-30 Diamyd Medical Bulletin from Annual General Meeting of Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2017-11-30 Diamyd Medical Kommuniké från årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2017-11-30 Diamyd Medical Preliminära 6-månadersresultat från DIAGNODE-1 innan jul Pressreleaser Ladda ner | Visa Stäng
2017-11-30 Diamyd Medical Preliminary 6-month results from DIAGNODE-1 before Christmas Pressreleaser Ladda ner | Visa Stäng
2017-11-21 Diamyd Medical The website www.diagnode-2.com launched for recruitment of patients for DIAGNODE-2 trial Pressreleaser Ladda ner | Visa Stäng
2017-11-21 Diamyd Medical Webbplatsen www.diagnode-2.com lanserad för patientrekrytering till studien DIAGNODE-2 Pressreleaser Ladda ner | Visa Stäng
2017-11-14 Diamyd Medical Diamyd Medicals vd har köpt aktier i Bolaget Pressreleaser Ladda ner | Visa Stäng
2017-11-14 Diamyd Medical Diamyd Medical's CEO purchased shares in the Company Pressreleaser Ladda ner | Visa Stäng
2017-11-13 Diamyd Medical Fas II-studien DIAGNODE-2 är nu inför Världsdiabetesdagen öppen att ta in patienter Pressreleaser Ladda ner | Visa Stäng
2017-11-13 Diamyd Medical Phase II-trial DIAGNODE-2 ahead of World Diabetes Day now open to include patients Pressreleaser Ladda ner | Visa Stäng
2017-11-09 Diamyd Medical Årsredovisning 16/17 Rapporter Ladda ner | Visa Stäng
2017-11-02 Diamyd Medical Kallelse till årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2017-10-27 Diamyd Medical Update concerning prevention studies with the diabetes vaccine Diamyd® Pressreleaser Ladda ner | Visa Stäng
2017-10-27 Diamyd Medical Uppdatering avseende preventionsstudier med diabetesvaccinet Diamyd® Pressreleaser Ladda ner | Visa Stäng
2017-10-24 Diamyd Medical Diamyd Medical strengthens GABA portfolio with new license Pressreleaser Ladda ner | Visa Stäng
2017-10-24 Diamyd Medical Diamyd Medical stärker GABA-portföljen med ny licens Pressreleaser Ladda ner | Visa Stäng
2017-10-11 Diamyd Medical Financial Statement 16/17 Rapporter Ladda ner | Visa Stäng
2017-10-11 Diamyd Medical Bokslutskommuniké 16/17 Rapporter Ladda ner | Visa Stäng

Kommande händelser

10 Oct 2018 | Bokslutskommuniké 2018
15 Nov 2018 | Årsstämma 2018
16 Nov 2018 | Årligutdelning
23 Jan 2019 | Kvartalsrapport 2019-Q1
27 Mar 2019 | Kvartalsrapport 2019-Q2
26 Jun 2019 | Kvartalsrapport 2019-Q3
2 Oct 2019 | Bokslutskommuniké 2019
21 Nov 2019 | Årsstämma 2019
22 Nov 2019 | Årligutdelning
22 Jan 2020 | Kvartalsrapport 2020-Q1
25 Mar 2020 | Kvartalsrapport 2020-Q2
24 Jun 2020 | Kvartalsrapport 2020-Q3
7 Oct 2020 | Bokslutskommuniké 2020

epaccess.penser.se använder cookies för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Vad är cookies?

Jag godkänner